Zhejiang Tianyu Pharmaceutical Management
Management criteria checks 4/4
Zhejiang Tianyu Pharmaceutical's CEO is Yong Jun Tu, appointed in Feb 2003, has a tenure of 21.83 years. directly owns 19.65% of the company’s shares, worth CN¥1.15B. The average tenure of the management team and the board of directors is 8 years and 6.6 years respectively.
Key information
Yong Jun Tu
Chief executive officer
CN¥1.0m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 21.8yrs |
| CEO ownership | 19.7% |
| Management average tenure | 8yrs |
| Board average tenure | 6.6yrs |
Recent management updates
Recent updates
Zhejiang Tianyu Pharmaceutical Co., Ltd.'s (SZSE:300702) Price Is Right But Growth Is Lacking
Dec 03
We Think Zhejiang Tianyu Pharmaceutical (SZSE:300702) Is Taking Some Risk With Its Debt
Nov 04Concerns Surrounding Zhejiang Tianyu Pharmaceutical's (SZSE:300702) Performance
Sep 04Take Care Before Diving Into The Deep End On Zhejiang Tianyu Pharmaceutical Co., Ltd. (SZSE:300702)
Aug 21Further Upside For Zhejiang Tianyu Pharmaceutical Co., Ltd. (SZSE:300702) Shares Could Introduce Price Risks After 27% Bounce
May 21Zhejiang Tianyu Pharmaceutical Co., Ltd.'s (SZSE:300702) Revenues Are Not Doing Enough For Some Investors
Mar 17CEO
Yong Jun Tu (61 yo)
21.8yrs
Tenure
CN¥1,018,000
Compensation
Mr. Tu Yong Jun serves as Chairman of the Board and General Manager at Zhejiang Tianyu Pharmaceutical Co., Ltd., since February 2003. Mr. Tu served as General Manager in Lin Hai Tian Yu Pharmaceutical Comp...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & GM | 21.8yrs | CN¥1.02m | 19.65% CN¥ 1.2b | |
| Financial Director | 3.7yrs | CN¥782.30k | no data | |
| Deputy GM & Non-Independent Director | 8.5yrs | CN¥759.00k | 0.033% CN¥ 1.9m | |
| Deputy GM & Non-Independent Director | no data | CN¥758.20k | 0.0094% CN¥ 549.1k | |
| Deputy General Manager | no data | CN¥620.00k | no data | |
| Board Secretary & Deputy GM | 7.6yrs | CN¥744.30k | 0.033% CN¥ 1.9m |
8.0yrs
Average Tenure
49.5yo
Average Age
Experienced Management: 300702's management team is seasoned and experienced (8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & GM | 13.8yrs | CN¥1.02m | 19.65% CN¥ 1.2b | |
| Deputy GM & Non-Independent Director | 1.6yrs | CN¥759.00k | 0.033% CN¥ 1.9m | |
| Deputy GM & Non-Independent Director | 1.6yrs | CN¥758.20k | 0.0094% CN¥ 549.1k | |
| Director | 21.8yrs | CN¥788.00k | 35.48% CN¥ 2.1b | |
| Non-Employee Supervisor | 13.6yrs | no data | 0.88% CN¥ 51.4m | |
| Member of Non-Employee Supervisory Board | 10.6yrs | no data | no data | |
| Employee Representative Member of Supervisory Board | 13.6yrs | no data | no data | |
| Independent Director | 2.6yrs | CN¥100.00k | no data | |
| Independent Director | 1.6yrs | CN¥66.70k | no data | |
| Independent Director | 2.6yrs | CN¥100.00k | no data |
6.6yrs
Average Tenure
51yo
Average Age
Experienced Board: 300702's board of directors are considered experienced (6.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 12:40 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zhejiang Tianyu Pharmaceutical Co., Ltd. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kai Wang | Citic Securities Co., Ltd. |
| Xiao Wei Lin | Everbright Securities Co. Ltd. |
| Wei Liu | Haitong International Research Limited |